Although several spontaneous case reports on the occurrence of thrombocytopenia in
patients treated with human granulocyte colony‐stimulating factor (G‐CSF) preparations …

Background MYL-1401H is a proposed pegfilgrastim biosimilar to the reference product EU-
Neulasta®, based on physicochemical characterization, in vitro bioassays, toxicokinetics …

Biosimilars can provide choices for patients and may provide cost savings; however, their
uptake has been slow in the USA, in part due to limited knowledge. To provide additional …

MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim
(Neulasta®). This study was designed primarily to compare the immunogenicity of …

e20735 Background: Empegfilgrastim is an innovator drug product of pegylated G-CSF
indicated for prophylaxis of neutropenia in patients receiving myelosuppressive …

Introduction: Pegfilgrastim is indicated in patients receiving myelosuppressive anticancer
drugs to reduce the Duration of Severe Neutropenia (DSN) and incidence of Febrile …

Background Recombinant human granulocyte-colony stimulating factor (G-CSF, filgrastim) is
used primarily to reduce incidence and duration of severe neutropenia and its associated …

6113 Background: In pivotal trials, appropriate use of pegfilgrastim and filgrastim prevented
neutropenic complications when initiated in cycle (C) 1, 24h after chemotherapy (CT). In …

8137 Background: Though pegfilgrastim has reduced the number of injections compared
with filgrastim, eliminating an office visit to receive pegfilgrastim on the day after …

Background Following the functional and physicochemical characterization of a proposed
biosimilar, comparative clinical studies help to confirm biosimilarity by demonstrating similar …